Oncimmune Germany GmbH.
General information
Oncimmune Germany GmbH.
Otto-Hahn-Straße 15
44227 Dortmund, North Rhine-Westphalia
Germany
Contact person: Rita Monaghan, Chief Financial Officer
Company main phone: +49 (231) 97426300
Company main fax: +49 (231) 97426301
Website: https://oncimmune.com
Otto-Hahn-Straße 15
44227 Dortmund, North Rhine-Westphalia
Germany
Contact person: Rita Monaghan, Chief Financial Officer
Company main phone: +49 (231) 97426300
Company main fax: +49 (231) 97426301
Website: https://oncimmune.com
| Source of foundation: | Subsidiary |
| Name of foundation source: | Oncimmune Holdings plc |
Corporate description / mission:
Oncimmune is dedicated to the development of precision diagnostic tools that aid therapeutic development and facilitate improved treatment strategies in the areas of immuno-oncology and autoimmune disease. The company focuses on the assay development programs on disease-specific autoantibodies.
Oncimmune is dedicated to the development of precision diagnostic tools that aid therapeutic development and facilitate improved treatment strategies in the areas of immuno-oncology and autoimmune disease. The company focuses on the assay development programs on disease-specific autoantibodies.
State of ownership: Subsidiary
Headquarters: HQ: No
Headquarters: HQ: No
Remarks on ownership / listings
Previously known as Protagen AG; acquired by Oncimmune in 2019.
Previously known as Protagen AG; acquired by Oncimmune in 2019.
Categorization
| Sector: |
|
| Subsector: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Description of products:
EarlyCDT® Lung is an extensively validated test for the levels of seven autoantibodies to tumour-associated antigens.
EarlyCDT® Lung is an extensively validated test for the levels of seven autoantibodies to tumour-associated antigens.
Technology used:
SeroTag Platform
SeroTag Platform
© 2024 Biotechgate by Venture Valuation